2. Search Result
Search Result
Results for "

adverse effect

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

3

Peptides

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124473
    Naphthofluorescein

    Naphthafluorescein

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    Naphthofluorescein inhibits the interaction between HIF-1 and Mint3. Naphthofluorescein suppresses Mint3-dependent HIF-1 activity and glycolysis in cancer cells and macrophages without cytotoxicity in vitro and adverse effect in vivo . Naphthofluorescein is also a fluorescent pH-sensitive probe that can be used for functional Cerenkov imaging .
    Naphthofluorescein
  • HY-B2209B
    Hydroxocobalamin acetate
    1 Publications Verification

    Vitamin B12a acetate

    		 Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin acetate is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the research of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin acetate
  • HY-B2209
    Hydroxocobalamin
    1 Publications Verification

    Vitamin B12a

    		 Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin (Vitamin B12a) is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the treatment of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin
  • HY-145427
    NU5455

    		DNA-PK Cancer
    NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
    NU5455
  • HY-B2209C
    Hydroxocobalamin hydrochloride

    Vitamin B12a hydrochloride

    		 Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin hydrochloride is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the research of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin hydrochloride
  • HY-B2209A
    Hydroxocobalamin monohydrochloride
    1 Publications Verification

    Vitamin B12a monohydrochloride

    		 Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin monohydrochloride (Vitamin B12a monohydrochloride) is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the treatment of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin monohydrochloride
  • HY-B2209BR
    Hydroxocobalamin acetate (Standard)

    Vitamin B12a acetate (Standard)

    		 Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin (acetate) (Standard) is the analytical standard of Hydroxocobalamin (acetate). This product is intended for research and analytical applications. Hydroxocobalamin acetate is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the research of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin acetate (Standard)
  • HY-10277
    Odiparcil

    SB-424323

    		 Thrombin Cardiovascular Disease
    Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .
    Odiparcil
  • HY-P1812
    AUNP-12

    NP-12

    		 PD-1/PD-L1 Cancer
    AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
    AUNP-12
  • HY-146459
    Akt1-IN-1

    		Akt Cancer
    Akt1-IN-1 (compound 5b) is a potent and selective Akt1 inhibitor with an IC50 value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 µM). Akt1-IN-1 can be used for researching anticancer .
    Akt1-IN-1
  • HY-P1812A
    AUNP-12 TFA

    NP-12 TFA

    		 PD-1/PD-L1 Cancer
    AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) .
    AUNP-12 TFA
  • HY-106281A
    Bemfivastatin hemicalcium

    PPD 10558 hemicalcium

    		 HMG-CoA Reductase (HMGCR) Cardiovascular Disease Metabolic Disease
    Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of ≥320 mg/kg/d (rat developmental toxicity), ≥12.5 mg/kg/d (rabbit maternal toxicity), ≥25 mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.
    Bemfivastatin hemicalcium
  • HY-Y1054
    Magnesium stearate

    Stearic Acid Magnesium(II) Salt
    Magnesium stearate is a commonly used pharmaceutical lubricant. But Magnesium stearate leads to an adverse effect on bonding between particles. Magnesium stearate can be used as an excipient, such as lubricant. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs .
    Magnesium stearate
  • HY-106281
    Bemfivastatin

    PPD 10558

    		 HMG-CoA Reductase (HMGCR) Cardiovascular Disease Metabolic Disease
    Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320 mg/kg/day for rats developmental toxicity, 12.5 mg/kg/day for rabbits maternal toxicity, and 25 mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins .
    Bemfivastatin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: